Background/Aim Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOBMRI) further enhances the identification of additional hepatic nodules compared with computed tomography (CT) alone; however, the optimal treatment for such additional nodules remains unclear. We investigated the long-term oncological effect of aggressive treatment strategies for additional lesions identified using EOB-MRI in patients with hepatocellular carcinoma (HCC).
Methods Data from 522 patients diagnosed with solitary HCC using CT between January 2008 and December 2012 were retrospectively reviewed. Propensity score-matched (PSM) analysis was used to compare the oncologic outcomes between patients with solitary HCC and those with additional nodules on EOB-MRI after aggressive treatment (resection or radiofrequency ablation [RFA]).
Results Among the 383 patients included, 59 had additional nodules identified using EOB-MRI. Compared with patients with solitary HCC, those with additional nodules on EOB-MRI had elevated total bilirubin, aspartate transaminase, and alanine transaminase; had a lower platelet count, higher MELD score, and highly associated with liver cirrhosis (P<0.05). Regarding long-term outcomes, 59 patients with solitary HCC and those with additional nodules after PSM were compared. Disease-free survival (DFS) and overall survival (OS) were comparable between the two groups (DFS, 60.4 vs. 44.3 months, P=0.071; OS, 82.8 vs. 84.8 months, P=0.986).
Conclusion The aggressive treatment approach, either resection or RFA, for patients with additional nodules identified on EOBMRI was associated with long-term survival comparable with that for solitary HCC. However, further studies are required to confirm these findings.
The cross-sectional imaging findings play a crucial role in the diagnosis of hepatocellular carcinoma (HCC). Recent studies have shown that imaging findings of HCC are not only relevant for the diagnosis of HCC, but also for identifying genetic and pathologic characteristics and determining prognosis. Imaging findings such as rim arterial phase hyperenhancement, arterial phase peritumoral hyperenhancement, hepatobiliary phase peritumoral hypointensity, non-smooth tumor margin, low apparent diffusion coefficient, and the LR-M category of the Liver Imaging-Reporting and Data System have been reported to be associated with poor prognosis. In contrast, imaging findings such as enhancing capsule appearance, hepatobiliary phase hyperintensity, and fat in mass have been reported to be associated with a favorable prognosis. Most of these imaging findings were examined in retrospective, single-center studies that were not adequately validated. However, the imaging findings can be applied for deciding the treatment strategy for HCC, if their significance can be confirmed by a large multicenter study. In this literature, we would like to review imaging findings related to the prognosis of HCC as well as their associated clinicopathological characteristics.
Citations
Citations to this article as recorded by
A Nomogram Based on MRI Visual Decision Tree to Evaluate Vascular Endothelial Growth Factor in Hepatocellular Carcinoma Hanting Dai, Chuan Yan, Wanrong Huang, Yifan Pan, Feng Pan, Yamei Liu, Shunli Wang, Huifang Wang, Rongping Ye, Yueming Li Journal of Magnetic Resonance Imaging.2025; 61(2): 970. CrossRef
Prediction early recurrence of hepatocellular carcinoma after hepatectomy using gadoxetic acid-enhanced MRI and IVIM Da Guo, Liping Liu, Yu Jin European Journal of Radiology Open.2025; 14: 100643. CrossRef
Radiomics and machine learning based on preoperative MRI for predicting extrahepatic metastasis in hepatocellular carcinoma patients treated with transarterial chemoembolization Gang Peng, Xiaojing Cao, Xiaoyu Huang, Xiang Zhou European Journal of Radiology Open.2024; 12: 100551. CrossRef
Clinical Parameters Work Well as Predictive Factors for Atezolizumab and Bevacizumab Treatment in Hepatocellular Carcinoma Ji Yeon Lee, Pil Soo Sung Gut and Liver.2024; 18(4): 558. CrossRef
Advances in Understanding Hepatocellular Carcinoma Vasculature: Implications for Diagnosis, Prognostication, and Treatment Hyungjin Rhee, Young Nyun Park, Jin-Young Choi Korean Journal of Radiology.2024; 25(10): 887. CrossRef
Inter-reader agreement for CT/MRI LI-RADS category M imaging features: a systematic review and meta-analysis Dong Hwan Kim, Sang Hyun Choi Journal of Liver Cancer.2024; 24(2): 192. CrossRef
Gd-EOB-DTPA-enhanced MR imaging features of hepatocellular carcinoma in non-cirrhotic liver Mingyue Song, Yuhao Tao, Hanjun Zhang, Mingzhan Du, Lingchuan Guo, Chunhong Hu, Weiguo Zhang Magnetic Resonance Imaging.2024; 114: 110241. CrossRef
Prediction of PD-L1 expression in unresectable hepatocellular carcinoma with gadoxetic acid-enhanced MRI Jun Gu Kang, Kyunghwa Han, Taek Chung, Hyungjin Rhee European Journal of Radiology.2024; 181: 111772. CrossRef
The histopathological and molecular heterogeneity of hepatocellular
carcinoma: a narrative review Wonju Chung, Haeryoung Kim The Ewha Medical Journal.2024;[Epub] CrossRef
Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Features Can Predict Immune-Excluded Phenotype of Hepatocellular Carcinoma Eisuke Ueshima, Keitaro Sofue, Takahiro Kodama, Shuhei Yamamoto, Masato Komatsu, Shohei Komatsu, Nobuaki Ishihara, Akihiro Umeno, Takeru Yamaguchi, Masatoshi Hori, Takumi Fukumoto, Tetsuo Takehara, Takamichi Murakami Liver Cancer.2024; : 1. CrossRef
Imaging prognostication and tumor biology in hepatocellular carcinoma Diana Kadi, Marilyn F. Yamamoto, Emily C. Lerner, Hanyu Jiang, Kathryn J. Fowler, Mustafa R. Bashir Journal of Liver Cancer.2023; 23(2): 284. CrossRef
Conventional chemoembolization using Lipiodol-based regimens was introduced in the 1980s, and it is currently recommended as the primary treatment modality for patients with unresectable, intermediate, or locally advanced hepatocellular carcinoma (HCC) by the international guidelines. For better therapeutic efficacy and safety, chemoembolization should be performed as selectively as possible through tumor-feeding arteries, based on the detection of arterial supply to the HCC. With the technical advancement of flat-panel detector, cone-beam computed tomography (CBCT) is mounted on the C-arm of the angiographic machine. CBCT facilitates the detection of small occult HCCs and fine tumor-feeding arteries, recognition of extrahepatic collateral supply, navigation of a microcatheter to the target feeding arteries, prevention of non-target embolization, and intraprocedural assessment of the completeness of treatment with chemoembolization. These functions performed by CBCT ultimately improve the safety and efficacy of chemoembolization and may contribute to improving the prognosis of the patient with HCC.
Citations
Citations to this article as recorded by
Model Predicting Survival in Intermediate-Stage HCC Patients Reclassified for TACE Based on the 2022 BCLC Criteria Jihoon Kim, Jin-Hyoung Kim, Eunbyul Ko, Jeong-Yeon Kim, Byung Soo Im, Gun Ha Kim, Hee Ho Chu, Heung-Kyu Ko, Dong Il Gwon, Ji Hoon Shin, Ibrahim Alrashidi Cancers.2025; 17(5): 894. CrossRef
Transarterial Chemoembolization for Hepatocellular Carcinoma: 2023 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim Korean Journal of Radiology.2023; 24(7): 606. CrossRef
Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim Journal of Liver Cancer.2023; 23(2): 241. CrossRef
Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim Clinical and Molecular Hepatology.2023; 29(3): 521. CrossRef
The efficacy of TACE; how can automated feeder software help? Hassan Abdelsalam, Doaa M. Emara, Ehab M. Hassouna Egyptian Journal of Radiology and Nuclear Medicine.2022;[Epub] CrossRef
Young Youn Cho, Jung Hee Kwon, Jeong-Hoon Lee, Jeong Min Lee, Jae Young Lee, Hyo-Choel Kim, Jin Wook Chung, Won-mook Choi, Eun Ju Cho, Yoon Jun Kim, Jung-Hwan Yoon, Chung Yong Kim, Hyo-Suk Lee
J Liver Cancer. 2015;15(1):19-29. Published online March 31, 2015
Background/Aims This study compared the outcomes of patients with small hepatocellular
carcinomas (HCCs) who were treated using transarterial chemoembolization (TACE) or
radiofrequency ablation (RFA). Methods This was a post-hoc analysis of a prospective study that evaluated the diagnostic
efficacy of magnetic resonance imaging (MRI) and computed tomography (CT). We analyzed
41 small hepatic nodules in 32 patients that showed typical radiologic hallmarks on both CT
and gadoxate-enhanced MRI (typical nodules) and 25 small hepatic nodules from 22 patients
that showed atypical radiologic hallmarks on CT and typical radiologic hallmarks on MRI
(discrepant nodules). Results There were no significant differences in the baseline characteristics of the patients
with typical and discrepant nodules. Complete response rates 1 month after TACE or RFA were
75.0% (18/24) and 94.1% (16/17; P=0.20), respectively, for the patients with typical nodules
and 58.8% (10/17) and 100% (8/8; P=0.05), respectively, for the patients with discrepant
nodules. Treatment failure rates after TACE or RFA were 33.3% (8/24) and 5.8% (1/17; P=0.15),
respectively, for the patients with typical nodules and 47.0% (8/17) and 0.0% (0/8; P=0.02),
respectively, for the patients with discrepant nodules. Among patients achieving complete
response, there were no significant differences in the risk of marginal recurrence. Conclusions RFA provided higher complete response rates and significantly lower treatment failure rates than TACE for patients with discrepant nodules of HCC. Therefore, a treatment
modality such as RFA may be preferable for small HCCs which show discrepancy on two
imaging modalities.
Background/Aims The aim of this study is to evaluate the concordance of contrast-enhanced
ultrasonography (CEUS) and lipiodol computed tomography (L-CT) for the assessment of
viable hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). Methods We retrospectively reviewed the post-TACE CEUS and L-CT images of 65
consecutive HCCs in 41 patients to assess the presence of viable tumor tissue. Forty-seven
HCCs in 31 patients that underwent post-TACE L-CT within 4 weeks of the CEUS examination
were included. The degree of concordance between CEUS and L-CT and factors related to
concordance were analyzed. Results The overall concordance of CEUS and LDCT was 78.7% (37/47). The concordance with
L-CT for viable tumor and non-viable tumor tissue on CEUS was 95.2%, and 65.4% respectively
(P<0.013). Diffuse tumors had a tendency for non-concordance (P=0.066). Although 3 of 4
lesions located in the hepatic dome were non-concordant, the sample size was too small to
establish significance. The mean tumor size for concordant and non-concordant tumors was
2.9 and 3.0 cm, with no significant difference. Conclusions Although the concordance of CEUS and L-CT for viable tumor tissue was
high, the concordance for non-viable tumor tissue was relatively low. Prospective studies
using angiography as a gold standard should be performed in the future. (J Liver Cancer
2014;14:115-119)
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Worldwide, the surveillance program of HCC is well-established for the patients with high risk. The early stage of HCC has the highest likelihood for cure. It is therefore important to make the early diagnosis of HCC. The imaging criteria for the diagnosis of HCC have established detailing the characteristic enhancement pattern of HCC including hypervascularity in the arterial phase and washout in the portal or delayed phase of dynamic imaging. However, in the current practical guidelines, there are controversies for HCC smaller than 1 cm in size because of the low sensitivity of CT and MR for HCC smaller than 1 cm in size. Recent advances in CT and MR hardware and software allow for rapid acquisition times that can reduce many of motion artifacts. Furthermore, recently introduced hepatocyte-specific MR contrast agents have showed its superior efficacy in both detection and characterization of small focal liver lesion by providing both dynamic imaging and hepatobiliary phase imaging. So, we reviewed the diagnostic performance of CT and MRI for HCC smaller than 1 cm in size. In addition, we introduced our experience for HCC smaller than 1 cm in size.
Combined hepatocellular-cholangiocarcinoma (HCC-CC) is a rare tumor showing histological evidence of both
hepatocellular and biliary epithelial differentiation. Because of its rarity, there have been few reports about the
imaging findings of this tumor. The CT findings of the combined HCC-CC include well-defined tumor with signs
of malignancy such as hepatic hypervascularity, biliary obstruction, satellite nodules, and lymphadenopathy. Some
portions may show hypoattenuation on arterial phase, whereas other portions show delayed persistent
enhancement. The signal intensity of this tumor on magnetic resonance (MR) imaging is not specific. However,
when the tumor resembles cholangiocarcinoma on gross pathologic exam, it shows peripheral rim-like
enhancement, infiltrative margin, and portal vein invasion in patients with liver cirrhosis. On the other hand, when
the tumor has gross appearance of HCC, imaging findings are not helpful for diagnosis. Cross-sectional imagings
are helpful for predicting the predominant component of the combined HCC-CC and determining the treatment
strategy.
We describe a case of hepatoid adenocarcinoma of the stomach with liver metastasis mimicking hepatocellular carcinoma (HCC). Ultrasonography demonstrated an ill-defined heterogeneous hyperechoic mass at right lobe of the liver and high echoic thrombi that filled both portal veins. Contrast enhanced CT scan revealed an ill-defined low attenuated lesion in right lobe of the liver and left portal vein and posterior branch of right portal vein that were filled with low attenuated tumor thrombi. Diffuse and irregular wall thickening with enhancement was also visualized on the posterior wall of the stomach from cardia to angle. Endoscopic biopsy for gastric lesion and US-guided percutaneous core biopsy for hepatic mass were performed. Microscopic examination and immunohistochemical staining revealed aFP-producing hepatoid adenocarcinoma of the stomach and metastatic tumor of the liver.
We described a case of atypical hepatocellular carcinoma (HCC) in an AIDS patient. The patient presented with fever and leukocytosis and had no evidence of chronic hepatitis clinically and radiologically. Ultrasonography showed multiple variable sized low echoic nodules, which had low echoic peripheral halo, in both lobes of the liver. Contrast enhanced CT scan showed multiple well demarcated and low attenuated nodules in both lobes of the liver. Hepatic and portal veins were intact. Percutaneous core biopsy for hepatic nodules revealed cod-like distribution of malignant cells and HCC with trabecular type was finally diagnosed.